No data to show
XHKG
1643
Market cap27mUSD
Jun 16, Last price
0.37HKD
1D
2.82%
1Q
-17.05%
IPO
-65.89%
Name
Modern Chinese Medicine Group Co Ltd
Chart & Performance
P/E
20.71
P/S
0.94
EPS
0.02
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-0.43%
Revenues
214m
-37.78%
Net income
10m
-80.18%
CFO
0k
-100.00%
Dividend
May 25, 20220.0167 HKD/sh
Profile
Modern Chinese Medicine Group Co., Ltd., an investment holding company, produces and sells proprietary Chinese medicines for elderlies and aged-middle in the People's Republic of China. It offers therapeutics for the qi-deficiency and blood-statis, cardio-cerebrovascular, digestive and gastrointestinal, gynecological, respiratory system, and nervous system conditions. The company was founded in 1986 and is headquartered in Chengde, China. Modern Chinese Medicine Group Co., Ltd. is a subsidiary of Modern Biotechnology Group Holdings Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | 214,068 -37.78% | 344,075 -13.91% | 399,656 10.80% | |||||
Cost of revenue | 191,739 | 277,208 | 273,561 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | 22,329 | 66,867 | 126,095 | |||||
NOPBT Margin | 10.43% | 19.43% | 31.55% | |||||
Operating Taxes | 5,149 | 19,511 | 36,495 | |||||
Tax Rate | 23.06% | 29.18% | 28.94% | |||||
NOPAT | 17,180 | 47,356 | 89,600 | |||||
Net income | 9,670 -80.18% | 48,795 -44.44% | 87,829 7.40% | |||||
Dividends | (8,322) | |||||||
Dividend yield | 2.52% | |||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 66 | 72 | 393 | |||||
Long-term debt | 204 | 72 | 393 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 7,054 | |||||||
Net debt | (229,398) | (286,122) | (263,324) | |||||
| Cash flow | ||||||||
Cash from operating activities | 8,476 | 125,786 | ||||||
CAPEX | (5,098) | (11,723) | ||||||
Cash from investing activities | (4,192) | (11,048) | ||||||
Cash from financing activities | (326) | (8,726) | ||||||
FCF | (51,339) | (7,623) | 108,407 | |||||
| Balance | ||||||||
Cash | 229,668 | 286,266 | 282,256 | |||||
Long term investments | (18,146) | |||||||
Excess cash | 218,965 | 269,062 | 244,127 | |||||
Stockholders' equity | 375,551 | 379,328 | 299,147 | |||||
Invested Capital | 272,449 | 203,899 | 167,688 | |||||
ROIC | 7.21% | 25.49% | 50.88% | |||||
ROCE | 4.54% | 13.94% | 30.23% | |||||
| EV | ||||||||
Common stock shares outstanding | 600,000 | 600,000 | 600,000 | |||||
Price | 0.38 8.70% | 0.35 -37.27% | 0.55 -21.43% | |||||
Market cap | 225,000 8.70% | 207,000 -37.27% | 330,000 -20.61% | |||||
EV | (4,398) | (64,009) | 66,676 | |||||
EBITDA | 22,329 | 73,307 | 131,786 | |||||
EV/EBITDA | 0.51 | |||||||
Interest | 5 | 14 | ||||||
Interest/NOPBT | 0.01% | 0.01% | ||||||